Should I Buy Autoimmune Inc (ALT)? Finance YouTuber Analysis

The YouTuber is buying ALT, a biotech focused on obesity and liver diseases, seeing an opportunity after its shares plunged due to side effects in a 24-week trial. He believes the average weight loss results were better than the market reaction suggests, and that dose adjustments could mitigate side effects. He anticipates significant upside if the full 48-week trial results are positive, considering it's a potential billion-dollar drug candidate in a company valued under $200 million.

“considering this is a billion dollar drug candidate on a company valued at under 200 million any good news on that phase two test could be a big upside”

Altimmune is presented as a high-upside penny stock with a weight loss drug candidate just out of Phase 2 trials. Despite a 60% stock plunge due to a 24% dropout rate from GI side effects, the YouTuber views this as an opportunity. He notes the drug achieved 11% weight loss in 24 weeks, which is significant for a shorter trial, and believes that if side effects can be mitigated, the drug candidate, valued at a billion dollars, could offer massive upside for a company currently valued at only $250 million.

“considering it's a billion dollar drug candidate on a company valued at just 250 million dollars right now there could be some massive upside on a positive phase three results.”